Maximilian Heinz Beck

ORCID: 0000-0002-0400-0046 · 14 papers in corpus
article 2026
Additional file 1 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048940.v1

Supplementary Material 1.

article 2026
Additional file 1 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048940

Supplementary Material 1.

article 2026
Additional file 2 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048943

Supplementary Material 2.

article 2026
Additional file 2 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048943.v1

Supplementary Material 2.

article 2026
Additional file 3 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048946.v1

Supplementary Material 3.

article 2026
Additional file 3 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048946

Supplementary Material 3.

article 2026
Additional file 4 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048949.v1

Supplementary Material 4.

article 2026
Additional file 4 of Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.32048949

Supplementary Material 4.

article 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors
·doi:10.1016/j.ijgc.2025.103753
other 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.c.8428212.v1

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

other 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
·doi:10.6084/m9.figshare.c.8428212

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

other 2026
Characteristics and outcomes of patients with endometriosis and malignant or borderline ovarian tumors: real-world evidence from an ESGO centre of excellence
BMC cancer ·doi:10.1186/s12885-026-15980-w

BACKGROUND: Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis independently …

article 2026
Multimodal analysis reveals asynchronous aging dynamics between endometriosis-associated ovarian cancer and endometriosis patients
·doi:10.1186/s12916-026-05101-6

Abstract Background The malignant transformation of endometriosis into endometriosis-associated ovarian cancer (EAOC) is still of great interest among researchers. Despite the shared inflammatory and hormonal drivers, the cellular aging dyn…

2023
Real-World Evidence: How Long Do Our Patients Fast?-Results from a Prospective JAGO-NOGGO-Multicenter Analysis on Perioperative Fasting in 924 Patients with Malignant and Benign Gynecological Diseases.
Cancers ·doi:10.3390/cancers15041311

BackgroundDespite the key role of optimized fasting in modern perioperative patient management, little current data exist on perioperative fasting intervals in routine clinical practice.MethodsIn this multicenter prospective study, the leng…